Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) CEO Sells $10,560,000.00 in Stock

Key Points

• CEO Richard Francis sold 250,000 Teva shares for $10.56 million, reducing his ownership by 21.23% to 927,529 shares.
• Teva reported quarterly EPS of $0.86, beating the $0.72 consensus, and revenue of $4.39 billion versus estimates of $4.23 billion; revenue was down 1.9% year over year.
• Analyst sentiment was broadly positive: 13 of 15 analysts rated the stock a Buy, with a $48.15 consensus price target and a “Moderate Buy” consensus rating.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) CEO Richard Francis sold 250,000 shares of the stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $42.24, for a total value of $10,560,000.00. Following the completion of the sale, the chief executive officer owned 927,529 shares of the company's stock, valued at $39,178,824.96. This trade represents a 21.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Teva Pharmaceutical Industries Stock Up 0.7%

Shares of NYSE TEVA traded up $0.28 during mid-day trading on Thursday, reaching $43.52. 9,218,408 shares of the company's stock were exchanged, compared to its average volume of 6,859,138. Teva Pharmaceutical Industries Ltd. has a twelve month low of $24.01 and a twelve month high of $44.31. The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 1.59. The firm has a market capitalization of $50.72 billion, a price-to-earnings ratio of 101.22, a PEG ratio of 3.97 and a beta of 0.97. The business has a fifty day simple moving average of $39.88 and a 200 day simple moving average of $34.96.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The business had revenue of $4.39 billion during the quarter, compared to analyst estimates of $4.23 billion. During the same period in the previous year, the firm earned $0.78 EPS. Teva Pharmaceutical Industries's quarterly revenue was down 1.9% compared to the same quarter last year. As a group, equities analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TEVA has been the topic of a number of recent research reports. Zacks Research downgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "strong sell" rating in a report on Tuesday, October 20th. HC Wainwright began coverage on shares of Teva Pharmaceutical Industries in a research report on Monday, November 2nd. They issued a "buy" rating and a $52.00 target price for the company. Barclays lifted their price target on shares of Teva Pharmaceutical Industries from $42.00 to $47.00 and gave the company an "overweight" rating in a research note on Thursday, October 15th. Weiss Ratings raised shares of Teva Pharmaceutical Industries from a "hold (c)" rating to a "hold (c+)" rating in a research report on Wednesday, November 4th. Finally, TD Cowen increased their price objective on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a "buy" rating in a research note on Wednesday, November 4th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $48.15.

Key Teva Pharmaceutical Industries News

Here's some of the latest news about TEVA:

• Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and upgraded Teva to “overweight,” implying about 28% upside from the cited $43.74 share price. Piper Sandler ratings
• Neutral Sentiment: HC Wainwright made mixed earnings-estimate revisions: it raised its FY2027 EPS forecast to $3.07 from $3.03, but lowered estimates for some individual quarters, including Q4 2026 and Q3 2027. Its overall rating remains “Buy” with a $52 target. Teva analyst information
• Negative Sentiment: Healthcare shares were weaker in Wednesday afternoon trading, with the NYSE Healthcare Index down 0.6%, creating a possible sector-level headwind for TEVA. Healthcare sector update

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds have recently bought and sold shares of the company. Cornerstone Planning Group LLC lifted its stake in shares of Teva Pharmaceutical Industries by 547.1% during the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company's stock worth $27,000 after buying an additional 755 shares during the last quarter. Root Financial Partners LLC bought a new stake in shares of Teva Pharmaceutical Industries during the third quarter worth approximately $33,000. Western Wealth Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth approximately $43,000. Sunbelt Securities Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $45,000. Finally, EverSource Wealth Advisors LLC grew its position in shares of Teva Pharmaceutical Industries by 64.0% in the first quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company's stock valued at $50,000 after purchasing an additional 647 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.